Nathan Alamillo

Nathan Alamillo is a corporate attorney at Cooley LLP. He represents emerging growth companies and public companies on various matters throughout the company life cycle. His transactional practice includes corporate formation, venture capital financings, corporate governance, Securities and Exchange Commission reporting, and mergers and acquisitions.

According to the firm, Alamillo has worked on matters including Curevo Vaccine's acquisition by Eli Lilly and Company for up to $1.5 billion, Neurophos' oversubscribed $110 million Series A financing in photonic artificial intelligence chip technology, PassKey's strategic investment in indiGO Technologies, and Egnyte's strategic growth investment from GI Partners and TA Associates. He was also among the Cooley team members listed on Coterie's definitive agreement to be acquired by Mammoth Brands.

Alamillo's related services at the firm include corporate, private equity, and mergers and acquisitions work. He is admitted to practice in California, where he was admitted to the bar in 2023. Outside of his practice, the firm lists his interests as national parks, running and hiking, travel, and 1980s music.